Ipsoflog (Piroxicam)

Piroxicam works by non‑selectively inhibiting the cyclo‑oxygenase enzymes COX‑1 and COX‑2, which reduces the production of prostaglandins that mediate inflammation, pain and fever. Lower prostaglandin levels lead to decreased vascular permeability, edema and pain signalling in affected tissues.

The specific dose of Ipsoflog is determined by the prescribing clinician based on the patient’s condition, severity, age, renal and hepatic function, and other individual factors. Healthcare professionals set the appropriate dosage and frequency according to current clinical guidelines.

Safety data for piroxicam in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk, and a healthcare provider should be consulted before use in pregnant or nursing women.

To order Ipsoflog, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including cold‑chain if required) and any necessary import documentation.

Ipsoflog (piroxicam) has a relatively long half‑life compared with many NSAIDs such as ibuprofen or diclofenac, allowing once‑daily dosing in some formulations. Its anti‑inflammatory potency is comparable, but the risk profile for gastrointestinal and cardiovascular events is similar to other non‑selective NSAIDs, requiring the same precautionary measures.

Ipsoflog should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging to maintain stability and prevent contamination. If refrigeration is unavailable, consult the supplier for alternative storage guidance.

Ipsoflog is supplied as an injectable solution for intramuscular injection. A qualified healthcare professional administers the dose into a suitable muscle, typically the gluteal or deltoid region, using aseptic technique. The injection site should be monitored for pain, redness or swelling after administration.

The most serious risks include severe gastrointestinal ulceration or bleeding, hepatotoxicity manifested by elevated liver enzymes or hepatitis, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. Patients should be instructed to seek immediate medical attention if they experience signs of these conditions.

Ipsoflog should be avoided in patients with known hypersensitivity to piroxicam or other NSAIDs, active peptic ulcer disease, severe hepatic or renal impairment, and in those receiving anticoagulant therapy where bleeding risk is high. Caution is also advised for the elderly and for individuals with cardiovascular disease.